The MoneyTree™ Report is a quarterly study of venture capital investment activity in the United States. As a collaboration between PricewaterhouseCoopers and the National Venture Capital Association based upon data from Thomson Reuters, it is the only industry-endorsed research of its kind.
For the most recent quarter's results including VC and company lists, as well as aggregate trend data dating back to 1995, visit our interactive MoneyTree Report site: pwcmoneytree.com
Q4 2013: Internet Rising
Fourth quarter Technology venture capital investment jumped 47% year-over-year but fell 4% quarter-over-quarter.
Cleantech funding reached $357 million in the first quarter of 2014, with average deal size increasing 59 percent year-over-year. Funding was heavily weighted towards later stage funding; in fact, this was the only quarter where no disclosed first-time funding was invested in the industry since MoneyTree began tracking deals in 1995.
Q1 2014 Biotech deals rising
Investments increased year over year for biotech as well as medical devices. The average deal size for early stage medical device investments was the highest since 1995. However, life sciences investments underperformed total venture capital investments and are now at the lowest proportion of total investments since 2001.
With technology and innovation coming of age in many emerging countries, these fast-growing markets are important destinations for private equity. Together with our US MoneyTree™ Report, these reports will help you compare trends in various parts of the world and provide a truly global view of VC/PE investments. The global MoneyTree reports serve as a reliable source of current and recent trends in PE/VC funding for: Israel, India, Russia and China (debuting soon).